Today: 30 January 2026
Subscribe
Browse Category

NASDAQ:RGNX News 29 January 2026

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

New York, Jan 29, 2026, 15:20 EST — Regular session • Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in…
29 January 2026
·····

Stock Market Today

  • Viavi Solutions Shares Surge Over 17% on Strong Q2 Earnings Beat
    January 29, 2026, 9:01 PM EST. Viavi Solutions (VIAV) stock surged 17.76% after releasing its fiscal Q2 2026 results that surpassed analyst expectations. The tech equipment firm reported a 36% year-over-year revenue increase to $369 million and a 75% rise in adjusted net income to $51.5 million, or $0.22 per share, beating forecasts of $365 million and $0.19 respectively. Growth was driven by strong demand in data center and defense/aerospace sectors, particularly fueled by artificial intelligence infrastructure needs. The company also provided a robust outlook for Q3, expecting revenue between $386 million and $400 million and adjusted earnings per share of $0.22 to $0.24, well ahead of analyst averages. Viavi's performance coupled with favorable sector trends positions it as a noteworthy stock moving forward.
Go toTop